Seekyo Therapeutics
Tumor Activated Therapy: targeting Tumor Micro-Environment functional proteins to induce tumor self-destruction
Tumor Activated Therapy: targeting Tumor Micro-Environment functional proteins to induce tumor self-destruction
Seekyo is a biotechnology company founded in 2018 and headquartered in France. The company's slogan, "Tumor Activated Therapy: The next generation of targeted therapy for solid cancer," reflects its primary focus. Seekyo is dedicated to developing TUMOR ACTIVATED THERAPY, a highly selective treatment for solid tumors that aims to enhance efficacy while minimizing adverse effects, ultimately improving patients' Quality of Life. The company recently secured a €650.00K Seed Round investment on 18 March 2021, with Bpifrance as the primary investor. With its emphasis on cutting-edge biotechnology and commitment to advancing cancer treatment, Seekyo presents a compelling opportunity for venture capital investment.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Seed Round | €650.00K | 1 |
|
18 Mar 2021 |
| Debt Financing | €150.00K | 1 |
|
20 Jan 2020 |
| Seed Round | €650.00K | 1 | French Tech Acceleration Fund | 20 Jan 2020 |
No recent news or press coverage available for Seekyo Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.
